Colitis Induced in Mice with Dextran Sulfate Sodium (DSS) is Mediated by the NLRP3 Inflammasome
Overview
Authors
Affiliations
Background: The proinflammatory cytokines interleukin 1beta (IL-1beta) and IL-18 are central players in the pathogenesis of inflammatory bowel disease (IBD). In response to a variety of microbial components and crystalline substances, both cytokines are processed via the caspase-1-activating multiprotein complex, the NLRP3 inflammasome. Here, the role of the NLRP3 inflammasome in experimental colitis induced by dextran sodium sulfate (DSS) was examined.
Methods: IL-1beta production in response to DSS was studied in macrophages of wild-type, caspase-1(-/-), NLRP3(-/-), ASC(-/-), cathepsin B(-/-) or cathepsin L(-/-) mice. Colitis was induced in C57BL/6 and NLRP3(-/-) mice by oral DSS administration. A clinical disease activity score was evaluated daily. Histological colitis severity and expression of cytokines were determined in colonic tissue.
Results: Macrophages incubated with DSS in vitro secreted high levels of IL-1beta in a caspase-1-dependent manner. IL-1beta secretion was abrogated in macrophages lacking NLRP3, ASC or caspase-1, indicating that DSS activates caspase-1 via the NLRP3 inflammasome. Moreover, IL-1beta secretion was dependent on phagocytosis, lysosomal maturation, cathepsin B and L, and reactive oxygen species (ROS). After oral administration of DSS, NLRP3(-/-) mice developed a less severe colitis than wild-type mice and produced lower levels of proinflammatory cytokines in colonic tissue. Pharmacological inhibition of caspase-1 with pralnacasan achieved a level of mucosal protection comparable with NLRP3 deficiency.
Conclusions: The NLRP3 inflammasome was identified as a critical mechanism of intestinal inflammation in the DSS colitis model. The NLRP3 inflammasome may serve as a potential target for the development of novel therapeutics for patients with IBD.
Cao R, Zhou J, Liu J, Wang Y, Dai Y, Jiang Y Inflammation. 2025; .
PMID: 40085192 DOI: 10.1007/s10753-025-02282-9.
Feng Z, Chen Z, Wang X, Zhou M, Liu S Biomedicines. 2025; 13(2).
PMID: 40002889 PMC: 11853167. DOI: 10.3390/biomedicines13020476.
Zhuang J, Zhuang Z, Chen B, Yang Y, Chen H, Guan G Mol Med. 2025; 31(1):56.
PMID: 39934686 PMC: 11816829. DOI: 10.1186/s10020-025-01063-2.
Chen P, Wang Y, Tang H, Zhou C, Liu Z, Gao S J Pharm Anal. 2025; 15(1):101069.
PMID: 39902456 PMC: 11788862. DOI: 10.1016/j.jpha.2024.101069.
Wang Y, Wang J, Chen Y, Li X, Jiang Z Front Pharmacol. 2025; 15():1520040.
PMID: 39840084 PMC: 11747577. DOI: 10.3389/fphar.2024.1520040.